Hetero launches Favipiravir in India under the brand ‘Favivir’ to treat Covid-19

Hetero launches Favipiravir in India under the brand ‘Favivir’ to treat Covid-19 This is the second drug developed by Hetero after Covifor, the generic version of Remdesivir injection to be administered intravenously in a hospital for treatment of severe Covid-19, under the license from Gilead Sciences. https://ift.tt/eA8V8J